MedTrace Logo

ZW25 in Women With Endometrial Cancers

NCT04513665 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2025-05-22

Study results available
· View outcomes & findings →

Summary

This study is being done to test the drug ZW25 and look at whether this drug is effective in women with HER2-overexpressed endometrial cancer or carcinosarcoma that has been treated in the past.

Conditions

Interventions

DRUG

ZW25

ZW25 at 20mg/kg intravenously (IV) every two weeks.

Sponsors & Collaborators

Principal Investigators

  • Vikky Makker, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-12
Primary Completion
2024-03-08
Completion
2024-03-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04513665 on ClinicalTrials.gov